PUS7 and myelodysplastic syndrome: Guzzi and colleagues reported that the dysregulation of the terminal oligoguanine (TOG) at 5′-terminal end of tRFs, which is regulated by pseurouridine driven by PUS7 activity, is linked to leukemia transformation and reduced survival rates in patients and increases the risk of progressing from myelodysplastic syndrome (MDS) to acute myeloid leukemia [185].